Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 4Uveal Melanoma 2Neoplasms 2Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Monophenol Monooxygenase × Clear all
NCT00028431 2014-05-22

Novel Adjuvants for Peptide-Based Melanoma Vaccines

University of Southern California

Phase 1 Completed
19 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT00001685 2008-03-04

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
114 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡